Abcentra Announces First Patients Dosed with Orticumab in Clinical Trial Evaluating Blockade of Oxidized LDL in Psoriasis with Elevated Cardiometabolic Risk

LOS ANGELES: LOS ANGELES, Aug. 4, 2021 /PRNewswire/ -- Today, Abcentra LLC announced that the first patients have been dosed in its multi-center phase 2 trial assessing the safety and activity of orticumab in patients with moderate-to-severe plaque psoriasis and cardiometabolic risk factors. Orticumab is a fully-human monoclonal antibody against...

Click to view original post